Skip to content
Screener

Halozyme Therapeutics HALO Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$264.9MMiss by $16.1M
EPS$1.11Beat by $0.16
Revenue estimate$281.0M
EPS estimate$0.95

Next report

Nov 2, 2026 (in a month)
Revenue estimate$482.3M
EPS estimate$2.25

Financials

Q1 2025

Income statement

See full
Revenue$264.9M+35.2%
Gross profit$216.5M+29.2%
Operating income$141.5M+48.1%
Net income$118.1M+53.7%
EPS (diluted)$0.93+55.0%

Balance sheet

See full
Cash & equivalents$176.3M+7.1%
Total debt$1.5B+0.3%
Total equity$482.3M+171%
Total assets$2.2B+19.3%

Cash flow

See full
Operating cash flow$154.2M+19.2%
CapEx$950.0K-73.2%
Free cash flow$153.3M+21.8%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$7.88B+52.6%
Enterprise value$9.24B+41.5%
P/E16.2×0.0×
P/S7.3×+1.3×

Profitability

See full
Gross margin83.4%+4.9pp
Operating margin55.1%+11.1pp
Net margin44.8%+7.8pp
FCF margin45.7%-3.4pp

Returns & leverage

See full
Return on equity147.1%-115pp
Debt / equity3.2×-5.4×
Current ratio8.4×+1.8×

Segments

By product

See full
Royalties$168.2M+39.5%
Proprietary product sales$36.3M+3.1%
Bulk rHuPH20 sales$27.0M+157%
Sales-based milestones$15.0M—
Device partnered product sales$14.7M+14.5%

By geography

See full
All other foreign$8.3M+250%

FAQ

When did Halozyme Therapeutics report Q1 2025 earnings?
Halozyme Therapeutics (HALO) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Halozyme Therapeutics's Q1 2025 revenue and EPS?
Halozyme Therapeutics reported revenue of $264.9M and eps of $1.11 for Q1 2025.
Did Halozyme Therapeutics beat estimates in Q1 2025?
Revenue missed the consensus estimate of $281.0M by $16.1M. EPS beat the consensus estimate of $0.95 by $0.16.
How did Halozyme Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 35.2% from $195.9M a year earlier and eps grew 40.5% from $0.79.
Where can I find Halozyme Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001159036-25-000025) and the 10-Q periodic report (0001159036-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.